Hyperkinetic movement disorders

Drug Abuse and Addiction in Medical Illness: Causes, Consequences and Treatment

Volumn 9781461433750, Issue , 2012, Pages 421-429

  Hess, Christopher ^a   Saunders Pullman, Rachel ^b,c  

^a College of Physicians and Surgeons ^*  (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949176083     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3375-0_34     Document Type: Chapter

References (125)

1. Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone/Elsevier; 2007.
2. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985;35:949-56.
3. Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J. 2004;80:527-34.
4. Brust JCM. Neurological aspects of substance abuse. 2nd ed. Philadelphia, PA: Elsevier; 2004.
5. Kahlig KM, Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol. 2003;479:153-8.
6. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98.
7. Fasano A, Barra A, Nicosia P, et al. Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend. 2008;96:178-82.
8. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir. 1972;75:203-12.
9. Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med. 1988;6:131-3.
10. Sperling LS, Horowitz JL. Methamphetamine-induced choreoathetosis and rhabdomyolysis. Ann Intern Med. 1994;121:986.
11. Downes MA, Whyte IM. Amphetamine-induced movement disorder. Emerg Med Australas. 2005;17:277-80.
12. Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry. 1981;44:728-30.
13. Shen YC. Amphetamine as a risk factor for aripiprazole-induced acute dystonia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1756-7.
14. Brust JCM. Substance abuse and movement disorders. Mov Disord. 2010;25(13):2010-20.
15. Nestler EJ. The neurobiology of cocaine addiction. Sci Pract Perspect. 2005;3:4-10.
16. Factor SA, Sanchez-Ramos JR, Weiner WJ. Cocaine and Tourette's syndrome. Ann Neurol. 1988;23:423-4.
17. Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord. 1993;8:175-8.
18. Attig E, Amyot R, Botez T. Cocaine induced chronic tics. J Neurol Neurosurg Psychiatry. 1994;57:1143-4.
19. Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology. 1990;40:999-1000.
20. Linazasoro G, Van Blercom N. Severe stuttering and motor tics responsive to cocaine. Parkinsonism Relat Disord. 2007;13:57-8.
21. Catalano G, Catalano MC, Rodriguez R. Dystonia associated with crack cocaine use. South Med J. 1997;90:1050-2.
22. Choy-Kwong M, Lipton RB. Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis. Neurology. 1989;39:996-7.
23. Farrell PE, Diehl AK. Acute dystonic reaction to crack cocaine. Ann Emerg Med. 1991;20:322.
24. Fines RE, Brady WJ, DeBehnke DJ. Cocaine-associated dystonic reaction. Am J Emerg Med. 1997;15:513-5.
25. Merab J. Acute dystonic reaction to cocaine. Am J Med. 1988;84:564.
26. Kumor K, Sherer M, Jaffe J. Haloperidol-induced dystonia in cocaine addicts. Lancet. 1986;2:1341-2.
27. Maat A, Fouwels A, de Haan L. Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol Bull. 2008;41:5-10.
28. van Harten PN, van Trier JC, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry. 1998;59:128-30.
29. Duggal HS. Cocaine use as a risk factor for ziprasidone-induced acute dystonia. Gen Hosp Psychiatry. 2007;29:278-9.
30. Henderson JB, Labbate L, Worley M. A case of acute dystonia after single dose of aripiprazole in a man with cocaine dependence. Am J Addict. 2007;16:244.
31. Daras M, Koppel BS, Atos-Radzion E. Cocaine-induced choreoathetoid movements ('crack dancing'). Neurology. 1994;44: 751-2.
32. Habal R, Sauter D, Olowe O, Daras M. Cocaine and chorea. Am J Emerg Med. 1991;9:618-20.
33. Kamath S, Bajaj N. Crack dancing in the United Kingdom: apropos a video case presentation. Mov Disord. 2007;22:1190-1.
34. Weiner WJ, Rabinstein A, Levin B, Weiner C, Shulman LM. Cocaine-induced persistent dyskinesias. Neurology. 2001;56: 964-5.
35. Bartzokis G, Beckson M, Wirshing DA, Lu PH, Foster JA, Mintz J. Choreoathetoid movements in cocaine dependence. Biol Psychiatry. 1999;45:1630-5.
36. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006;30:215-38.
37. Sethi KD. Drug-induced movement disorders. New York: Marcel Dekker; 2004.
38. Petzinger G, Mayer SA, Przedborski S. Fentanyl-induced dyskinesias. Mov Disord. 1995;10:679-80.
39. Ferris DJ. Controlling myoclonus after high-dosage morphine infusions. Am J Health Syst Pharm. 1999;56:1009-10.
40. Potter JM, Reid DB, Shaw RJ, Hackett P, Hickman PE. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ. 1989;299:150-3.
41. Gattera JA, Charles BG, Williams GM, Cavenagh JD, Smithurst BA, Luchjenbroers J. A retrospective study of risk factors of akathisia in terminally ill patients. J Pain Symptom Manage. 1994; 9:454-61.
42. Mercadante S. Opioids and akathisia. J Pain Symptom Manage. 1995;10:415.
43. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991;47:337-9.
44. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998;74:5-9.
45. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther. 2002;9:53-68.
46. Ito S, Liao S. Myoclonus associated with high-dose parenteral methadone. J Palliat Med. 2008;11:838-41.
47. Mercadante S. Dantrolene treatment of opioid-induced myoclonus. Anesth Analg. 1995;81:1307-8.
48. Sarhill N, Davis MP, Walsh D, Nouneh C. Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care. 2001;18: 51-3.
49. Bonnet U, Banger M, Wolstein J, Gastpar M. Choreoathetoid movements associated with rapid adjustment to methadone. Pharmacopsychiatry. 1998;31:143-5.
50. Clark JD, Elliott J. A case of a methadone-induced movement disorder. Clin J Pain. 2001;17:375-7.
51. Wasserman S, Yahr MD. Choreic movements induced by the use of methadone. Arch Neurol. 1980;37:727-8.
52. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96:678-85.
53. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol. 2005;5:79-86.
54. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs. 1986;18: 335-40.
55. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1988;1:273-7.
56. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology. 1998;19:241-51.
57. Cosentino C. Ecstasy and acute dystonia. Mov Disord. 2004;19: 1386-7; author reply 1387.
58. Priori A, Bertolasi L, Berardelli A, Manfredi M. Acute dystonic reaction to ecstasy. Mov Disord. 1995;10:353.
59. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol. 2002;17:309-12.
60. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl). 1998;139:261-8.
61. Cole JC, Sumnall HR. Altered states: the clinical effects of Ecstasy. Pharmacol Ther. 2003;98:35-58.
62. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ. 2001;165:917-28.
63. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci. 2003;23:9107-15.
64. Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Engl J Med. 1999;340:1443.
65. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science. 2002; 297:2260-3.
66. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Retraction. Science. 2003;301:1479.
67. Lozsadi DA, Forster A, Fletcher NA. Cannabis-induced propriospinal myoclonus. Mov Disord. 2004;19:708-9.
68. Chatterjee A, Almahrezi A, Ware M, Fitzcharles MA. A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. J Pain Symptom Manage. 2002;24:4-6.
69. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991;40:701-8.
70. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord. 2002;17:145-9.
71. Muller-Vahl KR. Cannabinoids reduce symptoms of Tourette's syndrome. Expert Opin Pharmacother. 2003;4:1717-25.
72. Muller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003;64:459-65.
73. Uribe Roca MC, Micheli F, Viotti R. Cannabis sativa and dystonia secondary to Wilson's disease. Mov Disord. 2005;20:113-5.
74. Huang MC, Lin HY, Chen CH. Dependence on zolpidem. Psychiatry Clin Neurosci. 2007;61:207-8.
75. Lightman SL. Phenobarbital dyskinesia. Postgrad Med J. 1978;54: 114-5.
76. McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA. Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med. 1981;10:290-7.
77. Shiigi Y, Casey DE. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates. Psychopharmacology (Berl). 1999;146:67-72.
78. Finch CK, Lobo BL. Acute inhalant-induced neurotoxicity with delayed recovery. Ann Pharmacother. 2005;39:169-72.
79. Bartolucci G, Pellettier JR. Glue sniffing and movement disorder. J Neurol Neurosurg Psychiatry. 1984;47:1259.
80. Neiman J, Lang AE, Fornazzari L, Carlen PL. Movement disorders in alcoholism: a review. Neurology. 1990;40:741-6.
81. Carlen PL, Lee MA, Jacob M, Livshits O. Parkinsonism provoked by alcoholism. Ann Neurol. 1981;9:84-6.
82. Lang AE, Marsden CD, Obeso JA, Parkes JD. Alcohol and Parkinson disease. Ann Neurol. 1982;12:254-6.
83. Luijckx GJ, Nieuwhof C, Troost J, Weber WE. Parkinsonism in alcohol withdrawal: case report and review of the literature. Clin Neurol Neurosurg. 1995;97:336-9.
84. Neiman J, Borg S, Wahlund LO. Parkinsonism and dyskinesias during ethanol withdrawal. Br J Addict. 1988;83:437-9.
85. Shandling M, Carlen PL, Lang AE. Parkinsonism in alcohol withdrawal: a follow-up study. Mov Disord. 1990;5:36-9.
86. Mullin PJ, Kershaw PW, Bolt JM. Choreoathetotic movement disorder in alcoholism. Br Med J. 1970;4:278-81.
87. Balldin J, Alling C, Gottfries CG, Lindstedt G, Langstrom G. Changes in dopamine receptor sensitivity in humans after heavy alcohol intake. Psychopharmacology (Berl). 1985;86:142-6.
88. Louis ED, Barnes LF, Ford B, Pullman SL, Yu Q. Ethnic differences in essential tremor. Arch Neurol. 2000;57:723-7.
89. Klebe S, Stolze H, Grensing K, Volkmann J, Wenzelburger R, Deuschl G. Influence of alcohol on gait in patients with essential tremor. Neurology. 2005;65:96-101.
90. Louis ED. Environmental epidemiology of essential tremor. Neuroepidemiology. 2008;31:139-49.
91. Lambert D, Waters CH. Essential tremor. Curr Treat Options Neurol. 1999;1:6-13.
92. Louis ED, Vonsattel JP. The emerging neuropathology of essential tremor. Mov Disord. 2008;23:174-82.
93. Tan EK, Schapira AH. Hunting for genes in essential tremor. Eur J Neurol. 2008;15:889-90.
94. Deuschl G, Elble RJ. The pathophysiology of essential tremor. Neurology. 2000;54:S14-20.
95. Jenkins IH, Bain PG, Colebatch JG, et al. A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol. 1993;34:82-90.
96. Louis ED, Shungu DC, Chan S, Mao X, Jurewicz EC, Watner D. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neurosci Lett. 2002;333:17-20.
97. Pagan FL, Butman JA, Dambrosia JM, Hallett M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology. 2003;60:1344-7.
98. Shin DH, Han BS, Kim HS, Lee PH. Diffusion tensor imaging in patients with essential tremor. Am J Neuroradiol. 2008;29:151-3.
99. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005;64:2008-20.
100. Critchley M. Observations on essential (heredofamial) tremor. Brain. 1949;72:113-39.
101. Koller WC. A new drug for treatment of essential tremor? Time will tell. Mayo Clin Proc. 1991;66:1085-7.
102. Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary essential tremor. Brain. 1994;117(Pt 4):805-24.
103. Growdon JH, Shahani BT, Young RR. The effect of alcohol on essential tremor. Neurology. 1975;25:259-62.
104. Boecker H, Weindl A, Leenders K, et al. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta Neurol Scand. 1996;93:387-92.
105. Kralic JE, Criswell HE, Osterman JL, et al. Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest. 2005;115:774-9.
106. Loewenstein Y. A possible role of olivary gap-junctions in the generation of physiological and pathological tremors. Mol Psychiatry. 2002;7:129-31.
107. Manto M, Laute MA. A possible mechanism for the bene ficial effect of ethanol in essential tremor. Eur J Neurol. 2008;15:697-705.
108. Nasrallah HA, Schroeder D, Petty F. Alcoholism secondary to essential tremor. J Clin Psychiatry. 1982;43:163-4.
109. Schroeder D, Nasrallah HA. High alcoholism rate in patients with essential tremor. Am J Psychiatry. 1982;139:1471-3.
110. Koller WC. Alcoholism in essential tremor. Neurology. 1983;33: 1074-6.
111. Rautakorpi I, Marttila RJ, Rinne UK. Alcohol consumption of patients with essential tremor. Acta Neurol Scand. 1983;68:177-9.
112. Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. Addict Biol. 2006;11:117-25.
113. Saunders-Pullman R, Ozelius L, Bressman SB. Inherited myoclonus- dystonia. Adv Neurol. 2002;89:185-91.
114. Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001;29:66-9.
115. Chan P, Gonzalez-Maeso J, Ruf F, Bishop DF, Hof PR, Sealfon SC. Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol. 2005;482:50-73.
116. Xiao J, LeDoux MS. Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan. Brain Res Mol Brain Res. 2003;119:132-43.
117. Asmus F, Zimprich A, Naumann M, et al. Inherited myoclonusdystonia syndrome: narrowing the 7q21-q31 locus in German families. Ann Neurol. 2001;49:121-4.
118. Doheny DO, Brin MF, Morrison CE, et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology. 2002;59: 1187-96.
119. Hedrich K, Meyer EM, Schule B, et al. Myoclonus-dystonia: detection of novel, recurrent, and de novo SGCE mutations. Neurology. 2004;62:1229-31.
120. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology. 2007;68:522-4.
121. Kyllerman M, Forsgren L, Sanner G, Holmgren G, Wahlstrom J, Drugge U. Alcohol-responsive myoclonic dystonia in a large family: dominant inheritance and phenotypic variation. Mov Disord. 1990;5:270-9.
122. Marechal L, Raux G, Dumanchin C, et al. Severe myoclonusdystonia syndrome associated with a novel epsilon-sarcoglycan gene truncating mutation. Am J Med Genet B Neuropsychiatr Genet. 2003;119B:114-7.
123. Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol. 1999;46:794-8.
124. Mahloudji M, Pikielny RT. Hereditary essential myoclonus. Brain. 1967;90:669-74.
125. Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord. 1996;11:119-24.